Clinical Trial Update: MAGIC Ruxolitinib for aGVHD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating ruxolitinib for acute graft-versus-host disease in patients undergoing allogeneic bone marrow transplantation, currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Ruxolitinib (Jakafi) (ruxolitinib)

Snippet

Sponsor: John Levine | Conditions: Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation | Phase 2 | Status: RECRUITING